Immunotoxin development

SMPT or sulfo-LC-SMPT has been used to develop conjugates for in vivo delivery of siRNA to hepatocytes (Rozema et al., 2007), in preparing an anti-CD25-immunotoxin conjugate (Mielke et al., 2007), and in preparing conjugates for selective depletion of donor lymphocytes in stem cell transplantation (Solomon et al., 2005). 

Xiang X, Phung Y, Feng M et al (2011) The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 6 el4640... 

Ghetie, M. A and Vitetta, E S (1994) Recent developments in immunotoxin therapy Curr Opinion Immunol. 6, 707-714... 

The development of monoclonal antibodies (mAbs) has revolutionized cancer treatment, and several mAbs are today approved for clinical use. Treatment resistance is often a problem in mAbs-treatment where multiple treatment series are necessary [100]. Dmg response can be increased by binding mAbs to cytotoxic compounds, such as protein toxins, forming immunotoxins (ITs) [101]. The historical problems with first and second generation ITs are largely solved by the use of recombinant DNA technology where chimeric proteins consisting of the Fv-ffagment of an antibody and... 

Human monoclonal antibodies are on the market both for therapeutic and diagnostic purposes. Why is it then necessary to develop immunotoxins ... 

This chapter will outline the development of immunotoxins and describe the preclinical development required for advancing VB4-845, an anti-EpCAM targeting scFv linked to a truncated form of Pseudomonas exotoxin A(252-608), into the clinic. 

Ricin (castor bean) immunotoxin has been developed to attack the CD5 T-cell antigen (present in T-cell and some B-cell malignancies) as well as the interleukin-2 receptor of cancerous tumors. Ne-urobiological applications of ricin involve the study of brain function via lesioning. It is also used as a reagent for pepsin and trypsin, and as a commercial mole killer. Historically, it has been used as a biochemical warfare agent. 

Asthma is the most prevalent chronic disease affecting children worldwide and its prevalence has tripled in the last 30 years. Though a genetic predisposition is generally believed essential for asthma to ensue, environmental exposures to immunotoxins have been demonstrated to play a role in the induction of asthma. Two studies have shown that children exposed to environmental tobacco smoke (ETS) have increased incidences of asthma. Young children (aged 2 months to 5 years) who are exposed to ETS are more than twice as likely to be sensitized and develop asthma than their cohorts who are not so exposed. I38,39 ... 

Immunotoxin Conjugate Specificity /Drug Cancer Company Development Status Reference ... 

---